RBI-4000’s potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development SAN DIEGO, Feb. 7, 2025 /PRNewswire/ — ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the ...
Eight month follow-up data published in Communications Medicine, a Nature portfolio journal Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for ...
Rabies is a zoonotic disease that remains an important public health problem worldwide and causes more than 70,000 human deaths each year. The causative agent of rabies is rabies virus (RV), a ...
Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate's novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis Replicate to provide GMP ...
SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA ...
Ebola, measles and rabies are serious threats to public health in developing countries. Despite different symptoms all of the diseases are caused by the same class of viruses that unlike most other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results